Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages

  Dietrich, Sascha ^a   Hüllein, Jennifer ^b   Hundemer, Michael ^a   Lehners, Nicola ^a   Jethwa, Alexander ^b   Capper, David ^a,b   Acker, Till ^c   Garvalov, Boyan K ^c   Andrulis, Mindaugas ^a   Blume, Carolin ^b   Schulte, Christoph ^d   Mandel, Thomas ^e   Meissner, Julia ^a   Fröhling, Stefan ^b   Von Kalle, Christof ^b   Glimm, Hanno ^b   Ho, Anthony D ^a   Zenz, Thorsten ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d Institute of Hematopathology Hamburg   (Germany)

^e Klinikum am Plattenwald   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BILIRUBIN; CLADRIBINE; HEMOGLOBIN; INTERLEUKIN 2 RECEPTOR ALPHA; K RAS PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH1 RECEPTOR; PENTOSTATIN; PREDNISOLONE; RITUXIMAB; TRANSCRIPTION FACTOR EZH2; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SULFONAMIDE; VALINE;

ADULT; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CASE REPORT; CYTOPENIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; GENE MUTATION; HAIRY CELL LEUKEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; ONCOGENE N RAS; PANCYTOPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; SINGLE DRUG DOSE; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; POINT MUTATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GLUTAMIC ACID; HUMANS; INDOLES; INDUCTION CHEMOTHERAPY; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TREATMENT OUTCOME; VALINE;

EID: 84883062033     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9495     Document Type: Article

References (19)

1. Dietrich S, Glimm H, Andrulis M, et al: BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038-2040, 2012
2. Ho AD, Grossmann M, Knauf W, et al: Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. Leukemia 3:718-723, 1989
3. Grever MR: How I treat hairy cell leukemia. Blood 115:21-28, 2010
4. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
5. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
6. Dearden CE, Else M, Catovsky D: Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52:21-24, 2011 (suppl 2)
7. Jones G, Parry-Jones N, Wilkins B, et al: Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156:186-195, 2012
8. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117-1121, 1990
9. Spiers AS, Moore D, Cassileth PA, et al: Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316:825-830, 1987
10. Else M, Dearden CE, Matutes E, et al: Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733-740, 2009
11. Gerrie AS, Zypchen LN, Connors JM: Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 119:1988-1991, 2012
12. Ho AD, Thaler J, Mandelli F, et al: Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha: The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 7:1533-1538, 1989
13. Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241-247, 2001
14. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305-2315, 2011
15. Tiacci E, Schiavoni G, Forconi F, et al: Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119:192-195, 2012
16. Xi L, Arons E, Navarro W, et al: Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 119:3330-3332, 2012
17. Saven A, Burian C, Adusumalli J, et al: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93:2471-2477, 1999
18. Saven A, Burian C, Koziol JA, et al: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918-1926, 1998
19. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215, 2012